Publications

Insights

Long-form writing on preclinical development, competitive intelligence, portfolio and indication decisions, and investor and partner readiness.

§ / Latest

Strategy team reviewing indication assessment frameworks across modality, target, and treatment context

April 7, 20267 min

What a Thorough Indication Assessment Actually Requires

Why modality, target, and treatment context must be evaluated together, common failure patterns, and why the assessment precedes the science.

Read article

More insights

Executive boardroom view from the buy side of biotech acquisition and partnership evaluation

March 24, 20268 min

What I Saw Evaluating Biotech Companies for Acquisition and Partnership

Patterns from evaluating biotech deals on the acquirer and partner side. Drivers of advancement, deal-breakers, and the evaluator perspective early-stage founders commonly underestimate.

Read

Insights · §02BridgeLine · N°2

The BridgeLine Brief

Strategy breakdowns, deal analysis, and drug development insights you won't find anywhere else. Written from inside the industry by someone who has built programs and evaluated companies firsthand. Plus updates when we publish new guides, tools, and resources for early-stage biotech teams.

By subscribing you agree to our Privacy Policy.

BridgeLine on LinkedIn.

Timothy Luongo·BridgeLine

§ / Engage

Contact

BridgeLine Translational. A remote practice, serving biotech clients worldwide.

Schedule a call →

info@bridgelinetranslational.com · bridgelinetranslational.com